Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada - PubMed (original) (raw)
. 2006 Dec 6;98(23):1694-706.
doi: 10.1093/jnci/djj465.
Affiliations
- PMID: 17148771
- DOI: 10.1093/jnci/djj465
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada
Harvey A Risch et al. J Natl Cancer Inst. 2006.
Abstract
Background: BRCA1 and BRCA2 mutations in general populations and in various types of cancers have not been well characterized. We investigated the presence of these mutations in unselected patients with newly diagnosed incident ovarian cancer in Ontario, Canada, with respect to cancers reported among their relatives.
Methods: A population series of 1171 unselected patients with incident ovarian cancer diagnosed between January 1, 1995, and December 31, 1999, in Ontario, Canada, was screened for germline mutations throughout the BRCA1 and BRCA2 genes. Screening involved testing for common variants, then protein truncation testing of long exons, and then denaturing gradient gel electrophoresis or denaturing high-performance liquid chromatography for the remainder of BRCA1 and BRCA2, respectively. Cox regression analysis was used to examine cancer outcomes reported by the case probands for their 8680 first-degree relatives. Population allele frequencies and relative risks (RRs) were derived from the regression results by an extension of Saunders-Begg methods. Age-specific Ontario cancer incidence rates were used to estimate cumulative incidence of cancer to age 80 years by mutation status.
Results: Among 977 patients with invasive ovarian cancer, 75 had BRCA1 mutations and 54 had BRCA2 mutations, for a total mutation frequency of 13.2% (95% confidence interval [CI] = 11.2% to 15.5%). Higher risks for various cancer types in the general Ontario population were associated with BRCA1 mutation carriage than with noncarriage, including ovarian (RR = 21, 95% CI = 12 to 36), female breast (RR = 11, 95% CI = 7.5 to 15), and testis (RR = 17, 95% CI = 1.3 to 230) cancers. Higher risks were also associated with BRCA2 mutation carriage than with noncarriage, particularly for ovarian (RR = 7.0, 95% CI = 3.1 to 16), female and male breast (RR = 4.6, 95% CI = 2.7 to 7.8, and RR = 102, 95% CI = 9.9 to 1050, respectively), and pancreatic (RR = 6.6, 95% CI = 1.9 to 23) cancers. Cancer risks differed according to the mutation's position in the gene. Estimated cumulative incidence to age 80 years among women carrying BRCA1 mutations was 24% for ovarian cancer and 90% for breast cancer and among women carrying BRCA2 mutations was 8.4% for ovarian cancer and 41% for breast cancer. For the general Ontario population, estimated carrier frequencies of BRCA1 and BRCA2 mutations, respectively, were 0.32% (95% CI = 0.23% to 0.45%) and 0.69% (95% CI = 0.43% to 1.10%).
Conclusions: BRCA1 and BRCA2 mutations may be more frequent in general populations than previously thought and may be associated with various types of cancers.
Comment in
- BRCA mutation frequency and penetrance: new data, old debate.
Offit K. Offit K. J Natl Cancer Inst. 2006 Dec 6;98(23):1675-7. doi: 10.1093/jnci/djj500. J Natl Cancer Inst. 2006. PMID: 17148764 No abstract available.
Similar articles
- The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Díez O, Alonso MC, Lazaro C, Blanco I, Sánchez-de-Abajo A, Caldés T, Blanco A, Graña B, Durán M, Velasco E, Chirivella I, Cardeñosa EE, Tejada MI, Beristain E, Miramar MD, Calvo MT, Martínez E, Guillén C, Salazar R, San Román C, Antoniou AC, Urioste M, Benítez J. Milne RL, et al. Clin Cancer Res. 2008 May 1;14(9):2861-9. doi: 10.1158/1078-0432.CCR-07-4436. Clin Cancer Res. 2008. PMID: 18451254 - Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K. Satagopan JM, et al. Clin Cancer Res. 2002 Dec;8(12):3776-81. Clin Cancer Res. 2002. PMID: 12473589 - Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT. Casey MJ, et al. Gynecol Oncol. 2005 May;97(2):457-67. doi: 10.1016/j.ygyno.2005.01.039. Gynecol Oncol. 2005. PMID: 15863145 - Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.
Liede A, Karlan BY, Narod SA. Liede A, et al. J Clin Oncol. 2004 Feb 15;22(4):735-42. doi: 10.1200/JCO.2004.05.055. J Clin Oncol. 2004. PMID: 14966099 Review. - Hereditary ovarian cancer.
Prat J, Ribé A, Gallardo A. Prat J, et al. Hum Pathol. 2005 Aug;36(8):861-70. doi: 10.1016/j.humpath.2005.06.006. Hum Pathol. 2005. PMID: 16112002 Review.
Cited by
- HLA gene polymorphism is a modifier of age-related breast cancer penetrance in carriers of BRCA1 pathogenic alleles.
Kuligina ES, Romanko AA, Jankevic T, Martianov AS, Ivantsov AO, Sokolova TN, Trofimov D, Kashyap A, Cybulski C, Lubiński J, Imyanitov EN. Kuligina ES, et al. Breast Cancer Res Treat. 2024 Sep 21. doi: 10.1007/s10549-024-07497-2. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39306605 - MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model.
Blackman A, Rees AC, Bowers RR, Jones CM, Vaena SG, Clark MA, Carter S, Villamor ED, Evans D, Emanuel AJ, Fullbright G, O'Malley MS, Carpenter RL, Long DT, Spruill LS, Romeo MJ, Orr BC, Helke KL, Delaney JR. Blackman A, et al. Cancer Res Commun. 2024 Sep 1;4(9):2525-2538. doi: 10.1158/2767-9764.CRC-24-0144. Cancer Res Commun. 2024. PMID: 39225558 Free PMC article. - The Effects of National Insurance Coverage Expansion and Genetic Counseling's Role on BRCA1/2 Mutation Tests in Breast Cancer Patients.
Jang SY, Kwak Y, Choi JY, Shin DS, Lee H, Kim M, Jung BY, Chae BJ, Yu J, Lee JE, Kim SW, Nam SJ, Ryu JM. Jang SY, et al. Cancers (Basel). 2024 May 14;16(10):1865. doi: 10.3390/cancers16101865. Cancers (Basel). 2024. PMID: 38791944 Free PMC article. - Understanding familial risk of pancreatic ductal adenocarcinoma.
Paranal RM, Wood LD, Klein AP, Roberts NJ. Paranal RM, et al. Fam Cancer. 2024 Apr 12. doi: 10.1007/s10689-024-00383-2. Online ahead of print. Fam Cancer. 2024. PMID: 38609521 Review. - Variants in BRCA1/2 in a hospital-based cohort in Chile and national literature review.
Martin FJ, Saffie IM, Hurtado MA, Avila-Jaque D, Lagos RA, Selman CA, Huserman JZ, Castillo VA, Chahuán BJ. Martin FJ, et al. Ecancermedicalscience. 2024 Mar 21;18:1683. doi: 10.3332/ecancer.2024.1683. eCollection 2024. Ecancermedicalscience. 2024. PMID: 38566764 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous